Lv1
80 积分 2025-09-23 加入
State-of-the-Art Review on Myelofibrosis Therapies
4天前
已完结
Cancer drug approvals and setbacks in 2025
11天前
已完结
Functional Outcomes After Localized Prostate Cancer Treatment
15天前
已完结
Prostate cancer
16天前
已关闭
Prostate cancer
20天前
已关闭
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
22天前
已完结
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
23天前
已完结
Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy
25天前
已完结
Intratumoural immunotherapy plus focal thermal ablation for localized prostate cancer
25天前
已完结
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial
25天前
已完结
皖公网安备34019202002308
